- Pre-clinical data on rodents indicate that a novel psychedelic molecule created by Clearmind Medicine ( NASDAQ: CMND ) led to improved energy expenditure, better fat utilization, and weight loss of 20%.
- Rodents treated with MEAI (5-methoxy-2-aminoindane) also had normalization of insulin levels, improved glucose tolerance, and reduced fat and triglycerides accumulation in the liver.
- SciSparc ( NASDAQ: SPRC ) manufactures CannAmide, an oral formulation of the endo-cannabinoid palmitoylethanolamide. The companies say there is a potential synergistic effect between MEAI and CannAmide based on prior studies.
- In September 2022, a patent application for treating metabolic syndromes including obesity with the two therapies was submitted.
- In December 2022, MEAI was granted a US patent for treating alcoholism .
For further details see:
Clearmind, SciSparc see positive pre-clinical efficacy for psychedelic obesity treatment